Quick Comparison

PEA (Palmitoylethanolamide)Vitamin D3
Half-Life1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability15-25 days
Typical DosageStandard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks.Standard: 2000-5000 IU daily. Optimal blood level: 40-60 ng/mL (100-150 nmol/L). Most adults need 4000-5000 IU to reach optimal levels. Take with fat for absorption. Get blood levels tested before supplementing — both deficiency and excess are harmful.
AdministrationOral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability.Oral (softgels, drops, tablets). D3 (cholecalciferol) preferred over D2 (ergocalciferol). Take with a fat-containing meal.
Research Papers10 papers10 papers
Categories

Mechanism of Action

PEA (Palmitoylethanolamide)

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.

Vitamin D3

Vitamin D (1,25-dihydroxyvitamin D3) crosses the blood-brain barrier and binds to vitamin D receptors (VDR), a nuclear receptor expressed on neurons, astrocytes, microglia, and oligodendrocytes. VDR heterodimerizes with RXR and binds vitamin D response elements (VDREs) to regulate transcription. It upregulates neurotrophic factors: GDNF (glial cell line-derived), NGF, NT-3 via CREB and other transcription factors. Vitamin D promotes serotonin synthesis by upregulating tryptophan hydroxylase 2 (TPH2) and dopamine synthesis via tyrosine hydroxylase. It reduces neuroinflammation by suppressing microglial IL-1beta, TNF-alpha, and iNOS, and supports calcium homeostasis via regulation of L-type voltage-gated calcium channels and calbindin-D28k. Vitamin D regulates over 200 genes including those for neuroprotection, synaptic plasticity, and myelination.

Risks & Safety

PEA (Palmitoylethanolamide)

Common

Very well-tolerated — rare side effects. Mild GI discomfort.

Serious

None documented. Over 30 clinical trials confirm excellent safety profile.

Rare

Skin rash.

Vitamin D3

Common

Generally very safe at standard doses.

Serious

Toxicity at very high doses (>10,000 IU daily for months) — causes hypercalcemia (nausea, kidney stones, cardiac arrhythmia).

Rare

Headache, metallic taste, nausea.

Full Profiles